Second generation direct acting antiviral agents improve clinical resource utilization required for hepatitis C eradication

2017 ◽  
Vol 66 (1) ◽  
pp. S296
Author(s):  
C. Mahoney ◽  
M. Crosby ◽  
S. Hartz ◽  
A. Palumbo ◽  
M. McLean
Keyword(s):  
Hepatitis C ◽  
Resource Utilization ◽  
Second Generation ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Clinical Resource ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0145953 ◽  
Author(s):  
Thanthima Suwanthawornkul ◽  
Thunyarat Anothaisintawee ◽  
Abhasnee Sobhonslidsuk ◽  
Ammarin Thakkinstian ◽  
Yot Teerawattananon
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Second Generation ◽  
Meta Analysis ◽  
Antiviral Agents ◽  
Genotype 1 ◽  
Direct Acting Antiviral ◽  
Treatment Naïve ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Effect on the adherence to concomitant medications after initiation of treatment with direct-acting antiviral agents against hepatitis C virus

2020 ◽  
Vol 43 (8) ◽  
pp. 418-425
Author(s):  
Maria Isabel Guzman Ramos ◽  
Mercedes Manzano-García ◽  
M. de las Aguas Robustillo-Cortés ◽  
Juan Antonio Pineda ◽  
Ramón Morillo-Verdugo
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Concomitant Medications ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Pangenotypic direct‐acting antiviral agents for mixed genotype hepatitis C infection: A real‐world effectiveness analysis

2021 ◽  
Author(s):  
Yuan‐Jie Ding ◽  
Chung‐Kuang Lu ◽  
Wei‐Ming Chen ◽  
Shui‐Yi Tung ◽  
Kuo‐Liang Wei ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Real World ◽  
Antiviral Agents ◽  
Hepatitis C Infection ◽  
Mixed Genotype ◽  
Direct Acting Antiviral ◽  
Effectiveness Analysis ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 432
Author(s):  
Lorenzo Onorato ◽  
Mariantonietta Pisaturo ◽  
Mario Starace ◽  
Carmine Minichini ◽  
Alessandra Di Fraia ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Clinical Problem ◽  
Narrative Review ◽  
Factors Associated ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
The Impact ◽  
Direct Acting Antiviral Agents

The availability of all oral direct acting antiviral agents (DAAs) has revolutionized the management of HCV infections in recent years, allowing to achieve a sustained virological response (SVR) in more than 95% of cases, irrespective of hepatitis C Virus (HCV) genotype or staging of liver disease. Although rare, the failure to the latest-generation regimens (grazoprevir/elbasvir, sofosbuvir/velpatasvir, pibrentasvir/glecaprevir) represents a serious clinical problem, since the data available in the literature on the virological characteristics and management of these patients are few. The aim of the present narrative review was to provide an overview of the impact of baseline RASs in patients treated with the latest-generation DAAs and to analyze the efficacy of the available retreatment strategies in those who have failed these regimens.

scholarly journals Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors

2021 ◽  
Vol 45 (1) ◽  
Author(s):  
Stephen Ejeh ◽  
Adamu Uzairu ◽  
Gideon Adamu Shallangwa ◽  
Stephen E. Abechi
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Binding Energy ◽  
Protease Inhibitor ◽  
Protease Inhibitors ◽  
Antiviral Agents ◽  
High Potency ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Abstract Background Hepatitis C virus (HCV) is a global medical condition that causes several life-threatening chronic diseases in the liver. The conventional interferon-free treatment regimens are currently in use by a blend of direct-acting antiviral agents (DAAs) aiming at the viral NS3 protease. However, major concerns may be the issue of DAA-resistant HCV strains and the limited availability to the DAAs due to their high price. Due to this crisis, the developments of a new molecule with high potency as an NS3/4A protease inhibitor of the hepatitis-C virus remain a high priority for medical research. This study aimed to use in-silico methods to identify high potent molecule as an NS3/4A protease inhibitor and investigating the binding energy of the identified molecule in comparison with approved direct-acting antiviral agents (Telaprevir, Simeprevir, and Voxilaprevir) through molecular docking. Results The model obtained by in-silico method have the following statistical records, coefficient of determination (r2) of 0.7704, cross-validation (q2LOO = 0.6914); external test set (r2(pred) = 0.7049) and Y-randomization assessment (cR2p = 0.7025). The results from the model were used to identify 12 new potential human HCV NS3/4A protease inhibitors, and it was observed that the identified molecule is well-fixed when docked with the receptor and was found to have the lowest binding energy of − 10.7, compared to approved direct-acting antiviral agents (Telaprevir, Simeprevir, and Voxilaprevir) with − 9.5, − 10.0, − 10.5 binding energy, respectively. Conclusion The binding affinity (− 10.7) of the newly identified molecule docked with 3D structures of HCV NS3/4a protease/helicase (PDB ID: 4A92) was found to be better than that of Telaprevir, Simeprevir, and Voxilaprevir (approved direct-acting antiviral agents) which are − 9.5, − 10.0, and − 10.5, respectively. Hence, a novel molecule was identified showing high potency as HCV NS3/4a protease inhibitors.

scholarly journals Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis

2016 ◽  
Vol 14 (12) ◽  
pp. 1821-1830.e6 ◽  
Author(s):  
Raoel Maan ◽  
Marjolein van Tilborg ◽  
Katja Deterding ◽  
Alnoor Ramji ◽  
Adriaan J. van der Meer ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Agents ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Chronic Hepatitis C Virus ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents
Sign in / Sign up

Export Citation Format

Share Document